glp 1 oral GLP-1s rapidly expanding user base Oral GLP-1 receptor agonists: competition

GLP-1 + GIP treatments should not be used by individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Li LC, Liang LM, Ji HY, Zhang C, Wang M, Liu HS

GLP-1RAs have been recognized as a new type of hypoglycemic drugs and widely used in the treatment of type 2 diabetes mellitus (T2DM)

Beyond their joint-specific effects, GLP-1RAs have demonstrated systemic anti-inflammatory properties by decreasing levels of C-reactive protein, IL-6, IL-1, and TNF-, and reducing macrophage infiltration into vascular tissues[22]

WHERE TO PLAY NEXT: MOST ATTRACTIVE GROWTH OPPORTUNITIES Where the Best Expansion Logic Sits Most Attractive Product Niches Most Attractive Customer Segments White Spaces and Unsaturated Opportunities High-Margin and Underpenetrated Pockets Most Promising Product Adjacencies 14

FIGURE 6 Plasma insulin levels sampled from the tail tended to rise from baseline about 60 min after application of semaglutide either i.v